Sofinnova Partners
Venture fund
- Stages
- Seed, Series A, Series B
- Cheque size
- EUR 2M to EUR 40M
- Based in
- France
- Focus
- Pharma & Drug Discovery, Devices & Robotics, Imaging & Diagnostics
Sofinnova Partners is a Paris based venture firm founded in 1972 and now a leading European investor in life sciences. With offices in London and Milan, it focuses on breakthrough biopharma and medtech, manages over four billion euros and has backed more than five hundred companies.
Europe's long standing life sciences fund spanning biotech and medtech.
Notable investments
- Cardiawave
- MedDay
- Highlife
The journey
How Sofinnova Partners got here, step by step.
1972
Firm founded
Sofinnova Partners was founded in Paris, beginning decades of life sciences venture investing in Europe.
2008
Sofinnova Capital VI closes
The firm closed a 260 million euro fund dedicated to early stage healthcare investment in Europe.
2012
Sofinnova Capital VII raised
A 240 million euro fund continued the flagship early stage healthcare strategy.
2015 to 2020
Fund strategy expands
Sofinnova broadened its offering across biopharma, medtech and industrial biotechnology.
2025
1.2 billion euro raise
Sofinnova announced a 1.2 billion euro raise, taking assets under management beyond four billion euros.
2025
More than 500 companies backed
The firm reported having backed more than five hundred companies since its founding.
Investors at similar stages
- 7wireVentures
Venture fund
- Andreessen Horowitz Bio + Health
Venture fund
- Bessemer Venture Partners
Venture fund
- CVS Health Ventures
Corporate venture
- Define Ventures
Venture fund
- Elad Gil
Angel investor